Health tech device supported by Houston-based organization hitches ride on SpaceX flight

space tech

The Butterfly iQ, a device developed with Baylor College of Medicine's Translational Research Institute for Space Health, is headed to the ISS. Photo courtesy of TRISH

An innovative ultrasonography device that has been developed with the future of space health in mind has hitched a ride on SpaceX's Dragon cargo resupply mission. The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine is supporting the product's first user demo in space.

The Butterfly iQ device was developed by Connecticut-based Butterfly Network Inc. (NYSE: BFLY) and is "the world's first handheld, single-probe whole-body ultrasound system using semiconductor technology," according to a press release.

TRISH has been supporting the device's development since the organization realized the impact it can have on astronauts' ability to administer their own health care.

"NASA is returning to the moon and our astronauts will need to be more self-reliant when it comes to medical care. TRISH is investing in innovations that enable healthcare to be provided in new ways," says Dr. Dorit Donoviel, director of TRISH, in the release. "On deep space missions, tools such as the Butterfly iQ will help the astronauts monitor themselves for concerns such as kidney stones, fluid in the lungs, blood clots and swelling of the optic nerve."

When the device reaches the International Space Station, the astronauts will provide feedback on how they used the device, the quality of the produced ultrasound images, and the efficiency of image acquisition.

"We're thrilled that TRISH has identified the potential of Butterfly iQ to advance care delivery in remote – and extremely remote – care settings. We are confident that the iQ's combination of diagnostic power, portability, reliability and ease of use will prove a useful addition to the medical toolkit of the International Space Station," said Dr. Todd Fruchterman, president and CEO of Butterfly Network, in the release. "It is an honor to know that a Butterfly device will help NASA safeguard the health of its incredible astronauts by providing actionable diagnostic insights."

The device was recently introduced into CHI St. Luke's Health point of cair practice — specifically for COVID-19 treatment. Dr. Jose Diaz-Gomez, an anesthesiologist and ultrasonography expert at the hospital, says the Butterfly iQ's portable ultrasonography technology has been a key diagnostic tool in his team's point of care for COVID-19 patients.

Moving beyond the pandemic, Diaz-Gomez explained the pertinent use of lower cost, portable ultrasound tools like Butterfly iQ to increase access to health care — even here on earth.

"In conditions that are dynamic, you want to have a diagnostic tool that, over time as you're treating a patient, you can see meaningful changes — good or bad," Diaz-Gomez previously told InnovationMap. "The pandemic has enabled us to use — from the initial care to when they are on the ventilator — ultrasonography to see the changes in the patient's' lungs."

TRISH is focused on identifying and supporting technologies like Butterfly iQ through its network of space health experts, BCM, and NASA, which recently granted renewal for its TRISH partnership granted renewal for its TRISH partnership earlier this year. NASA will continue to work with TRISH to conduct biomedical research geared at protecting astronauts in deep space through 2028.

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

Houston hospital taps new tech to provide more accurate COVID-19 diagnostics and treatment

hand held

With such a dynamic virus like COVID-19 that affects patients with different levels of severity, the first challenge doctors face when treating infected patients is assessing the situation. CHI St. Luke's Health has been implementing a new technology that allows its physicians better access to that initial diagnosis.

Dr. Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health and ultrasonography expert, says the Butterfly iQ's portable ultrasonography technology has been a key tool in his team's point of care for COVID-19 patients. Over the past few years, ultrasonography equipment has been evolving to be more portable and more accurate. That's what the Butterfly iQ technology provides, and Diaz-Gomez says his team was quick to realize how the technology can help in diagnostics and treatment of coronavirus patients.

A traditional approach to examining a patient's lungs would mean radiography, but Diaz-Gomez says his team saw the opportunity ultrasonography and these new, portable devices had on providing more accurate and timely diagnostics.

"In conditions that are dynamic, you want to have a diagnostic tool that, over time as you're treating a patient, you can see meaningful changes — good or bad," Diaz-Gomez says. "The pandemic has enabled us to use — from the initial care to when they are on the ventilator — ultrasonography to see the changes in the patient's' lungs."

Jose Diaz-Gomez is an anesthesiologist at CHI St. Luke's. Photo courtesy of CHI St. Luke's

The Butterfly iQ device is different from its ultrasound predecessors in that it's built to be more accurate, portable, easy to use, and low cost (even being made available for commercial purchase). According to Diaz-Gomez, he could train someone on the device in just a few hours.

Ahead of the pandemic, CHI St. Luke's had 20 of these devices and now has doubled that initial fleet. Along with the other non-Butterfly iQ ultrasonography devices, Diaz-Gomez's team has access to 70 ultrasonography devices — 80 percent of which are dedicated to COVID-19 patients.

"Our institution was very supportive of bringing a very robust roll-out program for point-of-care ultrasonography during the pandemic," Diaz-Gomez says. "We were able to incorporate 40 ultrasound devices — the Butterfly system. Not only that, we actually implemented a very rigorous infection control process to make sure we do it in a safe manner. You don't want to bring tools that will be another source of transmission from patient to patient."

While this new technology is continuing to make a difference in St. Luke's COVID units, Diaz-Gomez is already looking forward to the difference the devices will make post pandemic.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography."

The device, with its portability, low cost, and ease of use, also has an application for telemedicine and at-home health, and that's something that's exciting for Diaz-Gomez. However, both in his COVID units or in the home setting, the device is only as good as the clinician who's interpreting the images paired with the other diagnostics.

"The integration of ultrasonography with the clinical practice itself — it has to go hand in hand," Diaz-Gomez says. "The clinical decision will depend on that integration."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings